Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Alnylam Delays IND For RNAi Flu Therapy; Nastech RNAi Program Moves Forward

This article was originally published in The Pink Sheet Daily

Executive Summary

Nastech shows positive preclinical results with delivery technology for RNAi targeting influenza A.

You may also be interested in...



Renamed Nastech Turns To RNAi

Company to divest intranasal program rather than spin out.

Renamed Nastech Turns To RNAi

Company to divest intranasal program rather than spin out.

Nastech Finalizes Plans For RNAi Subsidiary To Focus On Phase II Inhaled Drug Programs

Restructuring includes spinning out RNAi business, reducing 30 percent of work force to conserve cash.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS066432

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel